On February 8, 2022 Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, reported that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to participate in two upcoming investor conferences in March 2022 (Press release, Beyond Air, FEB 8, 2022, View Source [SID1234607855]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for Upcoming Conference Presentations:

Event: 34th Annual Roth Conference
Date and Time: March 13-15, 2022
Location: Dana Point, California

Event: Oppenheimer 32nd Annual Healthcare Conference
Date and Time: March 15-16, 2022
Location: Virtual presentation is scheduled for Wednesday, March 16th at 10:00 AM ET
Please contact your representative at either Roth or Oppenheimer to schedule a one-on-one meeting with Beyond Air during the respective conference.

On February 8, 2022 Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, reported that VCN Biosciences, S.L.’s (VCN) VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. Food & Drug Administration (FDA) (Press release, Synthetic Biologics, FEB 8, 2022, View Source [SID1234607854]). This announcement follows Synthetic Biologics’ recent announcement that it had entered a definitive agreement to acquire VCN, which is subject to conditions that must be met prior to closing. VCN is developing a new oncolytic adenovirus (OV) platform designed to trigger tumor cell death and promote immune cell infiltration into tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The FDA’s Office of Orphan Products Development grants orphan status to drugs being developed to treat, diagnose or prevent a rare disease or condition affecting fewer than 200,000 people in the United States. Orphan Drug Designation is designed to provide drug developers with various benefits to support the development of novel drugs, including the potential for market exclusivity for seven years upon FDA approval, eligibility for tax credits for qualified clinical trials, waiver of application fees, reduced annual product fees, clinical protocol assistance and potential qualification for expedited development programs.

Steven Shallcross, Chief Executive Officer and Chief Financial Officer of Synthetic Biologics, commented, "We are pleased to report that VCN’s VCN-01 was granted Orphan Drug Designation for retinoblastoma by the FDA. We believe VCN-01 may represent a novel rescue therapy for patients who fail standard therapy, or may be used as an adjunct to chemotherapy, to provide improved outcomes for these patients. We are highly encouraged by the preliminary clinical data thus far and look forward to conducting a pivotal Phase 2/3 trial in these patients following our expected completion of the acquisition."

On February 8, 2022 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022 (Press release, Affimed, FEB 8, 2022, View Source,conferences%20during%20the%20month%20of [SID1234607853]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11th SVB Leerink 2022 Global Healthcare Conference (February 14 – 18, 2022)
Date: Wednesday, February 16, 2022
Presentation Time: 11:20 a.m. EST / 17:20 CET
Webcast: View Source
Location: Virtual

Citi’s 2022 Virtual Immuno-Oncology Summit (February 17, 2022)
Date: Thursday, February 17, 2022
Presentation Time: 2:30 p.m. EST / 20:30 CET
Webcast: View Source
Location: Virtual

For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.

On February 8, 2022 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Conference taking place February 14-17, 2022 (Press release, Soligenix, FEB 8, 2022, View Source [SID1234607851]). The presentation will be available to registered conference attendees for on-demand viewing beginning February 11, 2022 via the event platform link. Alternatively, an audio webcast of the Soligenix corporate presentation is available on the Company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key members of Soligenix management will hold one-on-one meetings throughout the conference. Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platform.

If you are unable to attend the conference and would like to schedule a meeting with management, please contact [email protected].

For more information about the BIO CEO & Investor Conference, please refer to the conference website at View Source

On February 8, 2022 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, reported that it will provide insight into its ADC platform and solid tumor pipeline during a live webcast from 9:00 to 11:00 a.m. EST (Press release, ADC Therapeutics, FEB 8, 2022, View Source [SID1234607850]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the webcast, Chris Martin, PhD, Chief Executive Officer, Patrick van Berkel, PhD, Senior Vice President of Research & Development, and Joseph Camardo, MD, Chief Medical Officer, will discuss the broad applicability and flexibility of the Company’s novel ADC technology and provide a deep dive on its portfolio of solid tumor programs including three clinical-stage assets (Cami, ADCT-901, and ADCT-601); ADCT-701, which is approaching the clinic; and a newly disclosed program, ADCT-212, an ADC targeting PSMA with potential utility in metastatic castrate-resistant prostate cancer (mCRPC).

The live webcast will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.